Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized 3-arm Trial (Double-blind Debio 4126, Placebo Control, and Open-label Debio 4126), to Assess the Efficacy and Safety of Debio 4126, a 12-week Octreotide Formulation, in Patients With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT06930625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06930625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized 3-arm Trial (Double-blind Debio 4126, Placebo Control, and Open-label Debio 4126), to Assess the Efficacy and Safety of Debio 4126, a 12-week Octreotide Formulation, in Patients With Acromegaly Previously Treated With Somatostatin Analogs
Lead sponsor
Debiopharm International SA
Phase
Phase 3
Overall status
Recruiting
Start date
November 26, 2025
Completion date
March 31, 2029
Enrollment
119 (estimated)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly